Contact John R. Schreiber, MD, MPH

Request An Appointment

John R. Schreiber, MD, MPH

Medical Director of Infection Control

Loading ratings
Practice Name Connecticut Children's Medical Center



Haverford College, 1976
Tulane University School of Public Health, 1979
Tulane University School of Medicine, 1980


Boston Children’s Hospital, 1980-1982


Boston Children’s Hospital, 1982-1985

Board Certifications

  • Pediatrics
  • Pediatric Infectious Diseases
  • Faculty Appointment

    Professor of Pediatrics, University of Connecticut School of Medicine

    Clinical Expertise

    Dr. Schreiber is the Medical Director of Infection Control at Connecticut Children’s and visiting Professor of Pediatrics at the University of Connecticut School of Medicine. Dr. Schreiber completed his Pediatric Residency and Infectious Diseases Fellowship at Boston Children’s Hospital. He was Chief of Infectious Diseases at Rainbow Babies and Children’s Hospital and Case Western Reserve University, where his NIH funded laboratory focused on the immune response to bacterial polysaccharides and conjugate vaccines and yielded more than 100 papers and abstracts. He was then Chair of Pediatrics at the University of Minnesota in Minneapolis, followed by a second stint as Chair of Pediatrics at Tufts Medical School and the Floating Hospital for Children in Boston. He received the Distinguished Service Award from the American Association of Immunologists in 2008 and 2012. He was interim Chief of Infectious Diseases at Connecticut Children’s Hospital from 2019-2022.

    Selected Publications

    • Lai ZZ, Kimmel R, Petersen S, Thomas S, Pier GB, Bezebah B, Luo R, Schreiber JR. Multi-valent human monoclonal antibody preparation against Pseudomonas aeruginosa derived from transgenic mice containing human immunoglobulin loci is protective against fatal pseudomonas sepsis caused by multiple serotypes. Vaccine 23; 3264-3271: 2005.

    • Latz Eicke, Franko J, Golenbock D, and Schreiber JR. Haemophilus influenzae type b-OMPC glycoconjugate vaccine induces cytokine production by engaging human TLR 2 and requires the presence of TLR2 for optimal immunogenicity. J Immunol 172; 2431-2438: 2004

    • Kaur KK, Chowdhury S, Greenspan N, Schreiber JR. Decreased expression of tumor necrosis factor family ligands and receptors involved in humoral immunity in preterm neonates. Blood; 110; 2948-54: 2007.

    • Lai ZZ, Schreiber JR. Antigen processing of pneumococcal glycoconjugate vaccines; the polysaccharide component enters the APC and is associated with MHC II. Vaccine 27; 2009: 3137-3144

    • Lai ZZ, Schreiber JR. TLR2 stimulation enhances the pneumococcal capsular polysaccharide antibody response to the pneumococcal CRM197 conjugate vaccine. Clinical and Vaccine Immunology 18; 2011: 724-729

    Patient Feedback

    The Patient Rating score is an average of all responses to physician related questions on our nationally-recognized Patient Satisfaction Survey . Responses are measured on a scale of 1 to 5, with 5 being the best score. Comments also are gathered from our Patient Satisfaction Survey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.


    Recent Blog Posts by John R. Schreiber, MD, MPH

    Back to Top
    Searching Animation